Limits...
Potential Role of Lipometabolism-Related MicroRNAs in Peripheral Blood Mononuclear Cells as Biomarkers for Coronary Artery Disease

View Article: PubMed Central - PubMed

ABSTRACT

Aim:: To explore the relationship between lipometabolism-related microRNAs (miRNAs) in peripheral blood mononuclear cells (PBMCs) and the presence of coronary artery disease (CAD).

Methods:: In the present study, 161 stable CAD patients and 149 health controls were enrolled. The expression levels of seven miRNAs (miR-21, miR-24, miR-29a, miR-33a, miR-34a, miR-103a, and miR-122) in PBMCs were qualified by quantitative real-time polymerase chain reaction (qRT-PCR). The miRNA markers that showed significant difference between the two groups were used for further analysis. The risk of miRNA contributing to the presence of CAD was estimated by univariate and multivariate logistic regression models. The area under the receiver operating characteristic curve (AUC) was used to evaluate diagnostic accuracy.

Results:: The expression levels of miR-24, miR-33a, miR-103a, and miR-122 in PBMCs were significantly increased in CAD patients compared with controls and were significantly correlated with blood lipids in both CAD patients and controls. The increased levels of miR-24 (adjusted OR = 1.32, 95% CI 1.07–1.62, P = 0.009), miR-33a (adjusted OR = 1.57, 95% CI 1.35–1.81, P < 0.001), miR-103a (adjusted OR = 1.01, 95% CI 1.01–1.02, P < 0.001), and miR-122 (adjusted OR = 1.03, 95% CI 1.01–1.04, P < 0.001) were associated with risk of CAD. We identified a miRNA panel (miR-24, miR-33, miR-103a, and miR-122) that provided a high diagnostic accuracy of CAD (AUC= 0.911, 95% CI 0.880–0.942).

Conclusion:: The increased expression levels of miR-24, miR-33a, miR-103a, and miR-122 in PBMCs are associated with risk of CAD. A panel of the four miRNAs has considerable clinical value in diagnosing stable CAD.

No MeSH data available.


Expression levels of miRNAs in PBMCs between CAD group and control group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5392481&req=5

Figure 1: Expression levels of miRNAs in PBMCs between CAD group and control group.

Mentions: The expression level of the seven selected miRNAs in the PBMCs of CAD patients and healthy controls were listed in Table 2. The expression levels of the miRNAs were logarithmic transformed for t-test. There are four miRNAs including miR-24, miR-33a, miR-103a, and miR-122 showed significant higher expression level among CAD patients than that among healthy controls (P < 0.001, Fig. 1). However, no significant difference was found for expression level of miR-21, miR-29a, and miR-34a between the two groups (P > 0.05). As the potential biomarker of CAD, the risk and clinical significance of miR-24, miR-33a, miR-103a, and miR-122 were evaluated in the further statistical analyses.


Potential Role of Lipometabolism-Related MicroRNAs in Peripheral Blood Mononuclear Cells as Biomarkers for Coronary Artery Disease
Expression levels of miRNAs in PBMCs between CAD group and control group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5392481&req=5

Figure 1: Expression levels of miRNAs in PBMCs between CAD group and control group.
Mentions: The expression level of the seven selected miRNAs in the PBMCs of CAD patients and healthy controls were listed in Table 2. The expression levels of the miRNAs were logarithmic transformed for t-test. There are four miRNAs including miR-24, miR-33a, miR-103a, and miR-122 showed significant higher expression level among CAD patients than that among healthy controls (P < 0.001, Fig. 1). However, no significant difference was found for expression level of miR-21, miR-29a, and miR-34a between the two groups (P > 0.05). As the potential biomarker of CAD, the risk and clinical significance of miR-24, miR-33a, miR-103a, and miR-122 were evaluated in the further statistical analyses.

View Article: PubMed Central - PubMed

ABSTRACT

Aim:: To explore the relationship between lipometabolism-related microRNAs (miRNAs) in peripheral blood mononuclear cells (PBMCs) and the presence of coronary artery disease (CAD).

Methods:: In the present study, 161 stable CAD patients and 149 health controls were enrolled. The expression levels of seven miRNAs (miR-21, miR-24, miR-29a, miR-33a, miR-34a, miR-103a, and miR-122) in PBMCs were qualified by quantitative real-time polymerase chain reaction (qRT-PCR). The miRNA markers that showed significant difference between the two groups were used for further analysis. The risk of miRNA contributing to the presence of CAD was estimated by univariate and multivariate logistic regression models. The area under the receiver operating characteristic curve (AUC) was used to evaluate diagnostic accuracy.

Results:: The expression levels of miR-24, miR-33a, miR-103a, and miR-122 in PBMCs were significantly increased in CAD patients compared with controls and were significantly correlated with blood lipids in both CAD patients and controls. The increased levels of miR-24 (adjusted OR = 1.32, 95% CI 1.07&ndash;1.62, P = 0.009), miR-33a (adjusted OR = 1.57, 95% CI 1.35&ndash;1.81, P &lt; 0.001), miR-103a (adjusted OR = 1.01, 95% CI 1.01&ndash;1.02, P &lt; 0.001), and miR-122 (adjusted OR = 1.03, 95% CI 1.01&ndash;1.04, P &lt; 0.001) were associated with risk of CAD. We identified a miRNA panel (miR-24, miR-33, miR-103a, and miR-122) that provided a high diagnostic accuracy of CAD (AUC= 0.911, 95% CI 0.880&ndash;0.942).

Conclusion:: The increased expression levels of miR-24, miR-33a, miR-103a, and miR-122 in PBMCs are associated with risk of CAD. A panel of the four miRNAs has considerable clinical value in diagnosing stable CAD.

No MeSH data available.